SCHEMBL6787759

SCHEMBL6787759

C/C(=C/C(=O)Nc1ccc([N+](=O)[O-])cc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.71
AKR1C3 P42330 3/20 0.53
AKR1C2 P52895 3/20 0.53
AKR1C4 P17516 1/20 0.53
AKR1C1 Q04828 1/20 0.53
MAPT P10636 5/20 0.50
CTSV O60911 3/20 0.50
CTSL P07711 3/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
GAA P10253 1/20 0.47
ANO1 Q5XXA6 1/20 0.46
ANO2 Q9NQ90 1/20 0.46
KCNK2 O95069 1/20 0.46
KCNK10 P57789 1/20 0.46
MYC P01106 1/20 0.46
MAX P61244 1/20 0.46
NPC1 O15118 1/20 0.44
TRPA1 O75762 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784799 0.92 TERT (0.71) TERTAKR1C3AKR1C2AKR1C4AKR1C1
SCHEMBL6787247 0.90 TERT (0.59) TERTAKR1C3AKR1C2AKR1C4AKR1C1
SCHEMBL4024783 0.85 TERT (0.80) TERTMAPTMEN1KMT2AALDH1A1
SCHEMBL6791660 0.84 TERT (0.57) TERTMAPTMEN1KMT2AGAA
SCHEMBL6786444 0.84 TERT (0.78) TERTMAPTMEN1KMT2AALDH1A1
SCHEMBL29966843 0.83 TERT (1.00) TERTAKR1C3AKR1C2AKR1C4AKR1C1
SCHEMBL4022937 0.83 TERT (1.00) TERTAKR1C3AKR1C2AKR1C4AKR1C1
SCHEMBL29355750 0.83 TERT (1.00) TERTAKR1C3AKR1C2AKR1C4AKR1C1
SCHEMBL16964998 0.83 TERT (1.00) TERTAKR1C3AKR1C2AKR1C4AKR1C1
SCHEMBL30760782 0.83 TERT (1.00) TERTAKR1C3AKR1C2AKR1C4AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885AKR1C3 1239/4885AKR1C2 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.